Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome

First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fev...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of clinical cases 2019-03, Vol.7 (6), p.705-716
Hauptverfasser: Martinez-Cabriales, Sylvia A, Shear, Neil H, Gonzalez-Moreno, Emmanuel I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 716
container_issue 6
container_start_page 705
container_title World journal of clinical cases
container_volume 7
creator Martinez-Cabriales, Sylvia A
Shear, Neil H
Gonzalez-Moreno, Emmanuel I
description First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.
doi_str_mv 10.12998/wjcc.v7.i6.705
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6448072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2207157996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-261d93742dbbe1cb3c6f000f33da49bea38276ed4303c2599ecbef7a98fee64e3</originalsourceid><addsrcrecordid>eNpVkUtPwzAQhC0EolXhzA3lyKEpfiR2fEFCFS-pEhc4W46zaV0lcbHToP57DIWqnPxJnp0d7SB0RfCMUCmL28-1MbNBzCyfCZyfoDFlWKSF5Pj0iEfoMoQ1xpgQnBPOztGIYckLzPIxelvYAXxiu8E1A7TQ9ZGTfgVJ5bfLxIM2vXXdNAEXbOc2K9tYPU10VyVhF3porYnQbnrXhghd5V0LF-is1k2Ay993gt4fH97mz-ni9ellfr9IDZOsTyknlWQio1VZAjElM7yOMWvGKp3JEjQrqOBQZQwzQ3MpwZRQCy2LGoBnwCbobu-72ZYtVCam97pRG29b7XfKaav-_3R2pZZuUDzLCixoNLj5NfDuYwuhV60NBppGd-C2QVGKBcmFlDxKb_dS410IHurDGoLVTx3quw41CGW5inXEievjdAf93_HZF1f-io0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2207157996</pqid></control><display><type>article</type><title>Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome</title><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Martinez-Cabriales, Sylvia A ; Shear, Neil H ; Gonzalez-Moreno, Emmanuel I</creator><creatorcontrib>Martinez-Cabriales, Sylvia A ; Shear, Neil H ; Gonzalez-Moreno, Emmanuel I</creatorcontrib><description>First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.</description><identifier>ISSN: 2307-8960</identifier><identifier>EISSN: 2307-8960</identifier><identifier>DOI: 10.12998/wjcc.v7.i6.705</identifier><identifier>PMID: 30968035</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Minireviews</subject><ispartof>World journal of clinical cases, 2019-03, Vol.7 (6), p.705-716</ispartof><rights>The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. 2019</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-261d93742dbbe1cb3c6f000f33da49bea38276ed4303c2599ecbef7a98fee64e3</citedby><cites>FETCH-LOGICAL-c393t-261d93742dbbe1cb3c6f000f33da49bea38276ed4303c2599ecbef7a98fee64e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448072/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448072/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30968035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinez-Cabriales, Sylvia A</creatorcontrib><creatorcontrib>Shear, Neil H</creatorcontrib><creatorcontrib>Gonzalez-Moreno, Emmanuel I</creatorcontrib><title>Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome</title><title>World journal of clinical cases</title><addtitle>World J Clin Cases</addtitle><description>First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.</description><subject>Minireviews</subject><issn>2307-8960</issn><issn>2307-8960</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkUtPwzAQhC0EolXhzA3lyKEpfiR2fEFCFS-pEhc4W46zaV0lcbHToP57DIWqnPxJnp0d7SB0RfCMUCmL28-1MbNBzCyfCZyfoDFlWKSF5Pj0iEfoMoQ1xpgQnBPOztGIYckLzPIxelvYAXxiu8E1A7TQ9ZGTfgVJ5bfLxIM2vXXdNAEXbOc2K9tYPU10VyVhF3porYnQbnrXhghd5V0LF-is1k2Ay993gt4fH97mz-ni9ellfr9IDZOsTyknlWQio1VZAjElM7yOMWvGKp3JEjQrqOBQZQwzQ3MpwZRQCy2LGoBnwCbobu-72ZYtVCam97pRG29b7XfKaav-_3R2pZZuUDzLCixoNLj5NfDuYwuhV60NBppGd-C2QVGKBcmFlDxKb_dS410IHurDGoLVTx3quw41CGW5inXEievjdAf93_HZF1f-io0</recordid><startdate>20190326</startdate><enddate>20190326</enddate><creator>Martinez-Cabriales, Sylvia A</creator><creator>Shear, Neil H</creator><creator>Gonzalez-Moreno, Emmanuel I</creator><general>Baishideng Publishing Group Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190326</creationdate><title>Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome</title><author>Martinez-Cabriales, Sylvia A ; Shear, Neil H ; Gonzalez-Moreno, Emmanuel I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-261d93742dbbe1cb3c6f000f33da49bea38276ed4303c2599ecbef7a98fee64e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Minireviews</topic><toplevel>online_resources</toplevel><creatorcontrib>Martinez-Cabriales, Sylvia A</creatorcontrib><creatorcontrib>Shear, Neil H</creatorcontrib><creatorcontrib>Gonzalez-Moreno, Emmanuel I</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of clinical cases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinez-Cabriales, Sylvia A</au><au>Shear, Neil H</au><au>Gonzalez-Moreno, Emmanuel I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome</atitle><jtitle>World journal of clinical cases</jtitle><addtitle>World J Clin Cases</addtitle><date>2019-03-26</date><risdate>2019</risdate><volume>7</volume><issue>6</issue><spage>705</spage><epage>716</epage><pages>705-716</pages><issn>2307-8960</issn><eissn>2307-8960</eissn><abstract>First described in 1996, the drug reaction, eosinophilia, and systemic symptoms syndrome (DReSS) is considered, along with Stevens-Johnson syndrome and toxic epidermal necrolysis, a severe cutaneous drug reaction. It is characterized by the presence of a maculopapular erythematous skin eruption, fever, lymphadenopathy, influenza-like symptoms, eosinophilia, and visceral involvement such as hepatitis, pneumonitis, myocarditis, pericarditis, nephritis, and colitis. The prognosis of patients with DReSS is related to the severity of visceral involvement. The mortality ranges from approximately 5% to 10%, and death is mainly due to liver failure, which is also the organ most commonly involved in this syndrome. Although it was previously hypothesized in 1994, DReSS syndrome can lead to reactivation of one or more human herpesvirus family members. Now being included as diagnostic criteria in a proposed diagnostic score system, this reactivation can be detected up to 2-3 wk after DReSS syndrome onset. Other causes of mortality in DReSS syndrome include myocardial or pulmonary lesions and hemophagocytosis. We reviewed the literature of previously reported case-series of DReSS and liver involvement, highlighting the pattern of liver damage, the treatment used, and the outcome.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>30968035</pmid><doi>10.12998/wjcc.v7.i6.705</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2307-8960
ispartof World journal of clinical cases, 2019-03, Vol.7 (6), p.705-716
issn 2307-8960
2307-8960
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6448072
source Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Minireviews
title Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20involvement%20in%20the%20drug%20reaction,%20eosinophilia,%20and%20systemic%20symptoms%20syndrome&rft.jtitle=World%20journal%20of%20clinical%20cases&rft.au=Martinez-Cabriales,%20Sylvia%20A&rft.date=2019-03-26&rft.volume=7&rft.issue=6&rft.spage=705&rft.epage=716&rft.pages=705-716&rft.issn=2307-8960&rft.eissn=2307-8960&rft_id=info:doi/10.12998/wjcc.v7.i6.705&rft_dat=%3Cproquest_pubme%3E2207157996%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2207157996&rft_id=info:pmid/30968035&rfr_iscdi=true